论文部分内容阅读
目的:评价头孢地尼与奥硝唑联用对盆腔炎患者的临床疗效和安全性。方法:选择2014年7月—2016年2月期间收治的盆腔炎患者患者94例作为研究对象,根据治疗方式的不同随机将患者分为对照组(n=47例)和观察组(n=47例);对照组患者均给予左氧氟沙星与奥硝唑联用治疗,观察组患者均给予头孢地尼与奥硝唑联用治疗,比较和评价两组患者治疗后的总有效率和不良反应的发生率。结果:观察组患者治疗后的总有效率为91.48%显著高于对照组为70.21%(P<0.05),不良反应的总发生率为17.02%低于对照组为31.91(P<0.05)。结论:采用头孢地尼与奥硝唑联用治疗盆腔炎患者,临床疗效和不良反应的发生率均优于左氧氟沙星与奥硝唑联用治疗。
Objective: To evaluate the clinical efficacy and safety of cefdinir combined with ornidazole in patients with pelvic inflammatory disease. Methods: A total of 94 patients with pelvic inflammatory disease were selected from July 2014 to February 2016. Patients were randomly divided into control group (n = 47) and observation group (n = 47) according to different treatment methods Patients in the control group were given levofloxacin and ornidazole combined treatment, the observation group were given cefdinir and ornidazole in combination therapy, the two groups were compared and evaluated the total effective rate and adverse reactions after treatment rate. Results: The total effective rate of the observation group after treatment was 91.48%, which was significantly higher than that of the control group (70.21%, P <0.05). The overall incidence of adverse reactions was 17.02%, which was lower than that of the control group (31.91, P <0.05). Conclusion: The combination of cefdinir and ornidazole in the treatment of pelvic inflammatory disease patients, the clinical efficacy and adverse reactions were better than the levofloxacin and ornidazole combination therapy.